Literature DB >> 29893245

Barriers and strategies to achieve a cure for HIV.

Matthew C Pitman1, Jillian S Y Lau2, James H McMahon3, Sharon R Lewin4.   

Abstract

9 years since the report of a cure for HIV after C-C chemokine receptor type 5 Δ32 stem cell transplantation, no other case of HIV cure has been reported, despite much research. However, substantial progress has been made in understanding the biology of the latent HIV reservoir, and in measuring the amount of virus that persists after antiretroviral therapy (ART) with increasingly sophisticated approaches. This knowledge is being translated into a long pipeline of clinical trials seeking to reduce viral persistence in participants on suppressive treatment and ultimately to allow safe cessation of ART. In this Review, we discuss the main barriers preventing the development of an HIV cure, methods used to measure HIV persistence in individuals on ART, clinical strategies that aim to cure HIV, and future directions for studies in the field of HIV cure research.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29893245      PMCID: PMC6559798          DOI: 10.1016/S2352-3018(18)30039-0

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  105 in total

1.  Viremic relapse after HIV-1 remission in a perinatally infected child.

Authors:  Katherine Luzuriaga; Hannah Gay; Carrie Ziemniak; Keri B Sanborn; Mohan Somasundaran; Kaitlin Rainwater-Lovett; John W Mellors; Daniel Rosenbloom; Deborah Persaud
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

2.  Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.

Authors:  Ann Wiegand; Jonathan Spindler; Feiyu F Hong; Wei Shao; Joshua C Cyktor; Anthony R Cillo; Elias K Halvas; John M Coffin; John W Mellors; Mary F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205

3.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

4.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Authors:  Zhen Wang; Qinghua Pan; Patrick Gendron; Weijun Zhu; Fei Guo; Shan Cen; Mark A Wainberg; Chen Liang
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

6.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Authors:  Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

7.  Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques.

Authors:  Luca Micci; Emily S Ryan; Rémi Fromentin; Steven E Bosinger; Justin L Harper; Tianyu He; Sara Paganini; Kirk A Easley; Ann Chahroudi; Clarisse Benne; Sanjeev Gumber; Colleen S McGary; Kenneth A Rogers; Claire Deleage; Carissa Lucero; Siddappa N Byrareddy; Cristian Apetrei; Jacob D Estes; Jeffrey D Lifson; Michael Piatak; Nicolas Chomont; Francois Villinger; Guido Silvestri; Jason M Brenchley; Mirko Paiardini
Journal:  J Clin Invest       Date:  2015-11-09       Impact factor: 14.808

8.  Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.

Authors:  Richard Brad Jones; Rachel O'Connor; Stefanie Mueller; Maria Foley; Gregory L Szeto; Dan Karel; Mathias Lichterfeld; Colin Kovacs; Mario A Ostrowski; Alicja Trocha; Darrell J Irvine; Bruce D Walker
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

9.  Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells.

Authors:  Kajsa Noyan; Son Nguyen; Michael R Betts; Anders Sönnerborg; Marcus Buggert
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

10.  HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim.

Authors:  Paul Castellano; Lisa Prevedel; Eliseo A Eugenin
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

View more
  41 in total

Review 1.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Authors:  Michael A Moso; Jenny L Anderson; Samantha Adikari; Lachlan R Gray; Georges Khoury; Judy J Chang; Jonathan C Jacobson; Anne M Ellett; Wan-Jung Cheng; Suha Saleh; John J Zaunders; Damian F J Purcell; Paul U Cameron; Melissa J Churchill; Sharon R Lewin; Hao K Lu
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

3.  Combination treatment prevents HIV re-emergence in monkeys.

Authors:  Sharon R Lewin
Journal:  Nature       Date:  2018-11       Impact factor: 49.962

4.  The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency.

Authors:  Luisa Mori; Katharine Jenike; Yang-Hui Jimmy Yeh; Benoît Lacombe; Chuan Li; Adam Getzler; Sonia Mediouni; Michael Cameron; Matthew Pipkin; Ya-Chi Ho; Bertha Cecilia Ramirez; Susana Valente
Journal:  J Virol       Date:  2020-11-25       Impact factor: 5.103

5.  PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients.

Authors:  Julien Pothlichet; Thierry Rose; Florence Bugault; Louise Jeammet; Annalisa Meola; Ahmed Haouz; Frederick Saul; David Geny; José Alcami; Ezequiel Ruiz-Mateos; Luc Teyton; Gérard Lambeau; Jacques Thèze
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

7.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

Review 8.  Peptide-Based Dual HIV and Coronavirus Entry Inhibitors.

Authors:  Huan Wang; Chao Wang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

9.  μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.

Authors:  Hannah S Sperber; Padma Priya Togarrati; Kyle A Raymond; Mohamed S Bouzidi; Renata Gilfanova; Alan G Gutierrez; Marcus O Muench; Satish K Pillai
Journal:  FASEB J       Date:  2020-09-09       Impact factor: 5.191

Review 10.  Pharmacology of HIV Cure: Site of Action.

Authors:  Aaron S Devanathan; Mackenzie L Cottrell
Journal:  Clin Pharmacol Ther       Date:  2021-03-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.